Systematic review: steroid withdrawal in anti‐TNF‐treated patients with inflammatory bowel disease

Bultman, Evelien; Kuipers, Ernst J.; Woude, Christien J. van der

doi:10.1111/j.1365-2036.2010.04373.x

Cited by 13 publications

(9 citation statements)

References 74 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 0 -ASA blocks production of prostaglandins and leukotrienes and is used to induce remission in active UC and is also useful in maintaining remission [14]. Systemic corticosteroids are useful for acute flare-ups of most forms of IBD [15]. Azathioprine is used as an immunomodulatory agent in IBD.…”

Section: Introductionmentioning

confidence: 99%

Mechanism of Regulation of Na-H Exchanger in Inflammatory Bowel Disease: Role of TLR-4 Signaling Mechanism

Siddique

Khan

2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanism of Regulation of Na-H Exchanger in Inflammatory Bowel Disease: Role of TLR-4 Signaling Mechanism

Siddique

Khan

2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…It is also used in a small number of patients as a long term maintenance treatment in patients who are refractory or intolerant to other treatments and in whom more extensive surgery is not a viable option. IFX treatment allows catch up growth and reduces steroid use in paediatric patients with CD 12–14 …”

Section: Introductionmentioning

confidence: 99%

A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease

Russell

Wilson

Loganathan

et al. 2011

Alimentary Pharmacology &Amp; Therapeutics

View full text Add to dashboard Cite

show abstract

“…A recent systematic review evaluated the steroid-sparing effect of anti-TNF agents in patients with IBD [39]. Authors reported that 30% of all adult patients treated with steroids and IFX at baseline were able to remain steroid free without further complications.…”

Section: Efficacy Beyond Clinical Remission: Hospitalization Surgerymentioning

confidence: 99%

Have Biologics Changed the Natural History of Crohn's Disease?

Mandel

Miheller

Müllner

et al. 2014

Dig Dis

View full text Add to dashboard Cite

Crohn's disease (CD) is a progressive condition, with most patients developing a penetrating or stricturing phenotype over time. The introduction of anti-tumor necrosis factor (TNF) therapies over the past 10-15 years, which was supported by accumulating evidence both from trials and clinical practice, has led to a significant change in patient management, monitoring, and treatment algorithms. Anti-TNF therapy was demonstrated to be effective for both luminal and fistulizing disease. Regular therapy with both infliximab and adalimumab was shown to increase the likelihood of clinical remission and mucosal healing, as well as to reduce the need for surgery and hospitalization in both clinical trials and clinical practice, especially in patients with pediatric-onset CD, shorter disease duration, and when used in combination with immunosuppressives. This has led to new treatment goals and to the use of early aggressive medical therapy in a selected group of patients with a worse prognosis. Exploratory clinical trials are underway to determine if further optimization of therapies and treatment beyond clinical remission leads to superior disease outcomes. However, more long-term clinical data are needed to assess whether an early, aggressive therapeutic strategy employing anti-TNF, alone or in combination with biologicals, can further improve long-term disease outcomes in both pediatric patients and young adults.

show abstract

Systematic review: steroid withdrawal in anti‐TNF‐treated patients with inflammatory bowel disease

Abstract: SUMMARY BackgroundThe increasing awareness of increased risk for opportunistic infections when combining several immunosuppressant drugs led to new treatment goals for inflammatory bowel disease including limited use of steroids.

Cited by 13 publications

References 74 publications

Mechanism of Regulation of Na-H Exchanger in Inflammatory Bowel Disease: Role of TLR-4 Signaling Mechanism

Mechanism of Regulation of Na-H Exchanger in Inflammatory Bowel Disease: Role of TLR-4 Signaling Mechanism

A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease

Have Biologics Changed the Natural History of Crohn's Disease?

Contact Info

Product

Resources

About